Lack of clarity over Teva Pharmaceutical Industries Ltd.'s liability in ongoing opioid litigation continues to weigh on the generic drug manufacturer as it works toward a financial turnaround. Despite executing on a sweeping cost savings program, continuing to pay down on a mountain of debt and progress stabilizing its North American generic drug business, the company's growth trajectory remains unclear.
Teva announced second quarter sales and earnings on 7 Aug. and, despite financial improvements in the underlying business, management could...








